Sophiris Bio Inc. (SHS.TO) Reports Fourth Quarter and Year-End 2012 Financial Results and Key Operational Highlights  
2/14/2013 7:22:20 AM

San Diego, California and Vancouver, British Columbia, February 13, 2013 – Sophiris Bio Inc. (Sophiris, TSX: SHS) (the “Company”), a biopharmaceutical company developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate), today announced financial results and recent key operational highlights for the fourth quarter and the year-ended December 31, 2012.